L&T-TECHNOLOGY-SVCS
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leading pure-play engineering services company, today announced that its award-winning healthcare solution Chest rAI™ in collaboration with global technology leader Intel Corporation.
Chest rAI™ , LTTS’ AI-based chest X-Ray analysis system to assist radiologists in improving speed and accuracy of diagnosis, will be fueled by the Intel OpenVINO Toolkit and AI Analytics Toolkit to run optimized AI inferencing models on 3rd Gen Intel Xeon Scalable processors with built in AI accelerators.
LTTS’ AI-infused solution enables radiologists by fast triaging abnormalities in X-Ray, annotating and automatic report generation with significantly improved performance. The benefits of Chest rAI™ include increased throughput with the ability to extract more actionable information and to reduce waiting time for radiologists.
LTTS recently entered into a strategic engagement with one of the largest teleradiology platforms in India - 5C Network Private Limited, wherein 5C Network will leverage Chest rAI™ to empower radiologists with accurate patient insights while saving time.
Abhishek Sinha, Chief Operating Officer and Member of the Board, L&T Technology Services, said, “The potential of digital engineering in transforming complex age-old problem statements of the healthcare industry into simpler and more sophisticated mechanisms is now available to all, while maintaining patient data privacy by taking advantage of Intel hardware-enhanced security technologies. With more investments and by leveraging our engineering expertise in the medical image processing segment, our commitment is to enable a complete transformation of the Indian public health diagnostics services landscape. This collaboration will benefit millions of people not just in the urban but also in the rural areas.”
Sudhir Bahl, Board Member and Chief Strategy Officer, 5C Network, said, “Our endeavor is to serve as a reliable diagnostic partner with technology enabled decision-making for the healthcare service providers in India. As the next phase of growth, we aim to empower our radiologists with the best of futuristic technologies so that it not only enhances our quality but also empowers them with technology-based support to achieve clinical excellence with reduced turnaround time. With LTTS’ Chest rAI™ on Intel’s AI stack, we aim to reach elevated industry benchmarks.”
Intel’s AI Builders Program is an ecosystem of industry-leading independent software vendors (ISVs), system integrators (SIs), original equipment manufacturers (OEMs), and enterprise end users who want to accelerate the adoption of AI across Intel platforms.
Wei Li, VP and GM of Machine Learning Performance at Intel Corporation, said, “Wherever customers need AI, Intel is already there with 3rd Gen Intel Xeon Scalable processors and an optimized software stack for the complete AI pipeline. With investments in tools, technologies, and a worldwide ecosystem of optimized solutions, we’re making AI more accessible than ever. Through the Intel AI Builders Program, we collaborate with companies across the globe to help bring cutting-edge AI solutions and capabilities to market.”
LTTS’ capabilities on digital technology led new-age innovations for radiologists is industry-leading. Earlier this year, Chest rAI™ was honored by the US-based BIG Innovation Award as an acknowledgement of the path-breaking technology capability possessed by the solution.
To know more about LTTS’ Chest rAI™ solution click here:
https://www.ltts.com/solutions/healthcare/AI-radiography/chest-rAI
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 16,900 employees spread across 17 global design centers, 28 global sales offices and 69 innovation labs as of June 30, 2021. For more information please visit https://www.ltts.com/ .
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005907/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom